Abstract
Mast cells are important in the development of allergic and anaphylactic reactions, but also in acquired and innate immunity. There is also increasing evidence that mast cells participate in inflammatory diseases, where they can be activated by non-allergic triggers, such as neuropeptides and cytokines, often having synergistic effects as in the case of substance P (SP) and IL-33. Secretion of vasoactive mediators, cytokines and proteinases contribute to the development of coronary artery disease (CAD), as well as to dietinduced obesity and the metabolic syndrome. Mast cells may be able to orchestrate such different biological processes through their ability to release pro-inflammatory mediators selectively without the degranulation typical of allergic reactions. Recent evidence suggests that mitochondrial uncoupling protein 2 (UCP2) and mitochondrial translocation regulate mast cell degranulation, but not selective mediator release. Better understanding of these two processes and how mast cells exert both immunostimulatory and immunosuppressive actions could lead to the development of inhibitors of release of specific mediators with novel therapeutic applications.
Keywords: Coronary artery disease, diabetes, inflammation, mast cells, mitochondria secretion
Current Pharmaceutical Design
Title:Mast Cells in Allergic and Inflammatory Diseases
Volume: 18 Issue: 16
Author(s): Nikolaos Sismanopoulos, Danae-Anastasia Delivanis, Konstantinos-Dionysios Alysandratos, Asimenia Angelidou, Anastasia Therianou, Dimitrios Kalogeromitros and Theoharis C. Theoharides
Affiliation:
Keywords: Coronary artery disease, diabetes, inflammation, mast cells, mitochondria secretion
Abstract: Mast cells are important in the development of allergic and anaphylactic reactions, but also in acquired and innate immunity. There is also increasing evidence that mast cells participate in inflammatory diseases, where they can be activated by non-allergic triggers, such as neuropeptides and cytokines, often having synergistic effects as in the case of substance P (SP) and IL-33. Secretion of vasoactive mediators, cytokines and proteinases contribute to the development of coronary artery disease (CAD), as well as to dietinduced obesity and the metabolic syndrome. Mast cells may be able to orchestrate such different biological processes through their ability to release pro-inflammatory mediators selectively without the degranulation typical of allergic reactions. Recent evidence suggests that mitochondrial uncoupling protein 2 (UCP2) and mitochondrial translocation regulate mast cell degranulation, but not selective mediator release. Better understanding of these two processes and how mast cells exert both immunostimulatory and immunosuppressive actions could lead to the development of inhibitors of release of specific mediators with novel therapeutic applications.
Export Options
About this article
Cite this article as:
Sismanopoulos Nikolaos, Delivanis Danae-Anastasia, Alysandratos Konstantinos-Dionysios, Angelidou Asimenia, Therianou Anastasia, Kalogeromitros Dimitrios and C. Theoharides Theoharis, Mast Cells in Allergic and Inflammatory Diseases, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800165997
DOI https://dx.doi.org/10.2174/138161212800165997 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Glycosaminoglycans as Key Molecules in Atherosclerosis: The Role of Versican and Hyaluronan
Current Medicinal Chemistry Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry Genetics of Congenital Heart Disease
Current Cardiology Reviews Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Recent Advances and Patents on Mechanical Circulatory Support Devices
Recent Patents on Biomedical Engineering (Discontinued)